Ask AI
ProCE Banner Activity

CE / CME

PI3K/AKT Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer (mBC)

PDF

Infographic resource with a brief overview of PI3K and AKT inhibitors for the management of patients with HR+/HER2- advanced breast cancer endocrine resistance and PI3K/AKT/PTEN alterations. 

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

European Learners: 0.25 hours EBAC® effective education time

Released: October 24, 2025

Expiration: April 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals caring for patients with breast cancer.

Program Learning Goal

This activity aims to improve learner knowledge, confidence, competence, and performance in optimizing therapy selection and mitigating therapy-related toxicities to extend treatment duration as part of optimal care of patients with PIK3CA-mut HR+/HER2- mBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the rationale for using PI3K/AKT/mTOR pathway inhibitors in HR+/HER2- metastatic breast cancer, including their mechanisms of action and clinical relevance in biomarker-selected populations

  • Develop individualized treatment plans based on biomarker testing, the latest clinical data, and patient-specific factors for patients with HR+/HER2- PIK3CA-mutated mBC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Giampaolo Bianchini, MD: consultant/advisor/speaker: Agendia, AstraZeneca, Daiichi Sankyo, Eisai, Exact Science, Gilead, Helsinn, Lilly, Menarini/Stemline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Seagen, Takeda, Tethis; researcher (paid to institution): Gilead; other financial or material support: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini/Stemline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 24, 2025, through April 23, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation

Clinical Care Options, LLC is an EBAC® accredited provider since 2025

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/65f35ab16f6ca.png

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.25 hours of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.